Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Document first published:
Page updated:
Topic:
Publication type:

Rituximab and eculizumab is recommended to be available as a treatment option through routine commissioning for delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies within the criteria set out in these documents.

Document

Clinical commissioning policy: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Clinical commissioning policy: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

  • PDF
  • 633 KB
  • 13 pages

Document

Evidence review: Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in patients of all ages with haemoglobinopathies

Evidence review: Prevention and Management of Delayed Haemolytic Transfusion Reactions and Hyperhaemolysis in patients of all ages with haemoglobinopathies

  • PDF
  • 481 KB
  • 37 pages

Document

Clinical panel report: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Clinical panel report: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

  • PDF
  • 33 KB
  • 2 pages

Document

Clinical priorities advisory group: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Clinical priorities advisory group: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

  • PDF
  • 93 KB
  • 12 pages

Document

Engagement Report: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Engagement Report: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

  • PDF
  • 65 KB
  • 3 pages

Document

Equality and health inequalities impact assessment: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Equality and health inequalities impact assessment: Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

  • PDF
  • 101 KB
  • 10 pages